SCHEMBL6988693

SCHEMBL6988693

O=C1CCN(S(=O)(=O)c2ccc(CC3SC(=O)NC3=O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
ALDH1A1 P00352 2/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KMT2A Q03164 2/20 0.48
HRH3 Q9Y5N1 1/20 0.47
PPARG P37231 7/20 0.47
FFAR1 O14842 5/20 0.44
PPARA Q07869 2/20 0.44
PTPN1 P18031 2/20 0.43
MEN1 O00255 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
HPGD P15428 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAOA P21397 2/20 0.43
CISD1 Q9NZ45 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6074524 0.80 MAPT (0.57) MAPTALDH1A1NPSR1KMT2AHRH3
SCHEMBL9570631 0.79 MAPT (0.67) MAPTALDH1A1NPSR1KMT2AHRH3
SCHEMBL9570559 0.77 MAPT (0.83) MAPTALDH1A1NPSR1KMT2AHRH3
SCHEMBL6075040 0.76 MAPT (0.63) MAPTALDH1A1NPSR1KMT2AHRH3
SCHEMBL9570641 0.74 MAPT (0.60) MAPTALDH1A1NPSR1KMT2AHRH3
SCHEMBL10483600 0.73 MAPT (0.58) MAPTALDH1A1NPSR1KMT2AHRH3
SCHEMBL6074651 0.72 ALDH1A1 (0.51) MAPTALDH1A1NPSR1KMT2AHRH3
SCHEMBL16111102 0.71 KMT2A (0.63) ALDH1A1KMT2AMEN1
SCHEMBL9372807 0.71 PPARG (0.60) MAPTALDH1A1NPSR1KMT2APPARG
SCHEMBL4852588 0.71 MAPT (0.73) MAPTALDH1A1NPSR1KMT2AHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6649603-B2 For therapy of metabolic disorders related to insulin resistance or hyperglycemia WYETH 2003-11-18 US disclosed
EP-1328512-A2 CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS Wyeth (US) 2003-07-23 EP disclosed
US-20030027797-A1 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists WYETH (US) 2003-02-06 US disclosed
US-6498170-B2 4-((2S)-3-(1-(4-BUTOXY-BENZENESULFONYL)-AZETIDIN-3-YLAMINO)-2 -HYDROXY- PROPOXY)-PHENOL FOR EXAMPLE; HYPOGLYCEMIC AGENT; INCREASING LEAN MEAT TO FAT RATIO IN MAMMALS WYETH 2002-12-24 US disclosed
US-20020022605-A1 Cyclamine sulfonamides as beta-3 adrenergic receptor agonists AMERICAN HOME PRODUCTS CORPORATION (US) 2002-02-21 US disclosed
WO-2002006221-A2 CYCLYLAMINE SULFONAMIDES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020022605-A1 Cyclamine sulfonamides as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 MAPT 4160/4885ALDH1A1 3013/4885NPSR1 24/4885
US-20030027797-A1 Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists ADRB3, ADRB1, ADRB2 MAPT 4279/4885ALDH1A1 2651/4885NPSR1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.